Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation ...

Peter Ronco, CEO, Emmes, explains how the company is investing in transparent goal setting, comprehensive education, and ...

Cashin, MD, chief operating officer, Novotech, explains why seamless collaboration between CROs and sponsors is critical to advancing clinical trials, and reflects on Novotech’s recognition as ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...

As wearable ECG technology advances, cardiac safety studies in clinical trials are evolving to capture richer, continuous ...

In an interview with ACT senior editor Andy Studna at the 2025 DIA Global Annual Meeting, Carie Pierce, SVP, global head of ...

In this Q&A, Megan Bailey, EVP and president of central laboratories and international, Labcorp, discusses how central labs ...

Balancing the emerging benefits of AI in pharmacovigilance with new responsibilities and demands from regulators in enhancing ...

In our June issue, explore how clinical research is adapting to regulatory changes, AI advancements, and modernizing trial ...

Brian Ongioni, chief product officer, uMotif, shares how early collaboration with patients and clinical sites helps shape intuitive, accessible digital health tools—and why co-design is key to ...

Peter Ronco, CEO, Emmes, explains why AI in clinical development still needs human oversight despite widespread hype.

Recent analysis explores AI's momentum in drug development, showcasing rapid adoption and significant time savings, despite ...